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Background: We aimed to evaluate the use of central catheters introduced by a peripheral vein (PICC) in children with CF.
Methods: A descriptive study in patients in whom a PICC (Beckton Dickinson) was inserted.
Results: 24 children aged (median (range) 10.2 years (0.3–17.3) undergoing 44 procedures were included. PICC was successfully inserted in
93.2% (41/44) of cases. Total procedure duration was (median (range)) 32.5 (10–105) minutes. The operators encountered few difficulties, median
(range) 2 (1–10) (1 (absence) to 10 (maximal)); median (range) 1 (1 to 5) attempt per child). No major side effects or infections were observed.
PICC obstruction in 5 (12%) cases was successfully unblocked in 4 cases (urokinase). The catheter was functional throughout the antibiotic course
in 40/41 cases. A final Doppler scan (30 cases) showed total permeability of the central veins in all cases. Satisfaction index of the operators and
the patients were high: median (range) 9.5 (1–10) and 8.0 (6–10) (scale: 1 (worse) to 10 (best)), respectively.
Conclusion: PICCs are simple to use, and may be safely inserted in the ward. Such catheters are well tolerated, may increase the well-being of
children with CF and prove an effective means by which to deliver IV therapy in this population.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Catheterization; Central venous; Cystic fibrosis; Anti-bacterial agents; Child; Quality of life1. Introduction
In patients with cystic fibrosis, colonisation of airways by P.
aeruginosa is deleterious and often requires prolonged
intravenous antibiotics. To treat chronic colonisation and/or
infection by P. aeruginosa, totally implantable devices are used
to increase the patients' comfort [1–4]. Nevertheless, they can
interfere with cosmetic appearance [2] and their insertion and
maintenance are not free of complications [5], including
catheter occlusion, deep venous thrombosis, local infection,
central sepsis, pneumothorax and air embolism [1–5]. We haveAbbreviations: CF, Cystic Fibrosis; IV, Intravenous; PICC, Peripherally
Inserted Central Catheter.
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doi:10.1016/j.jcf.2009.07.002previously observed rupture and migration of the distal end of
totally implantable devices inserted for a prolonged period of
time, a phenomenon also described by some authors [4–6].
Life-threatening complications may also be observed with
improper use of the device [5,6]. Therefore totally implantable
devices are usually inserted only when repeated courses of
antibiotic are required [1,3].
Short peripheral cannulae are frequently inserted in children,
who are not chronically colonised by P. aeruginosa. The high
doses of the various antibiotics administered increase the risk of
repeated insertions [7–10], which are painful and sometimes
technically difficult, especially in the youngest children.
In the past years, some authors have also studied peripheral
long lines, for antibiotics in CF, with a good tolerance and
acceptability [8,11–15]. However the introduction of the device
can be painful [14], and in some patients, the device was
removed due to discomfort [12].d by Elsevier B.V. All rights reserved.
Table 1
Demographic data and pulmonary function.
n 24
Delta F508/delta F508 14 (61)
Delta F508/severe mutation (type I, II, III) 5 (22)
Pancreatic insufficiency 21 (91)
Z score for weight 0.0 [−2.0 to 2.6]
Z score for height 0.1 [−1.8 to 2.5]
FEV1 (% reference values) 84±18 ⁎
N (%); median [range]; mean±SD.
* n=13 patients.
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used in neonates for more than 20 years, as well as in children
undergoing chemotherapy [16–19] or treatment for infectious
diseases [20]. It has been shown in such populations that PICCs
are more stable than short peripheral cannulae and need less
frequent replacement [7,9,16]. Their use has resulted in greater
comfort in young patients [9]. In cystic fibrosis (CF) PICC use
has previously been reported [21–24]. However their use in
specific CF paediatric populations has been rarely described
[24]. Since home antibiotic therapy increases the patients'
quality of life [25], we aimed to evaluate the feasibility and
tolerance of a new central catheters introduced by a peripheral
vein for home antibiotic treatment in our CF population.
1.1. Study design and patients
This prospective descriptive study was conducted at
Bordeaux University Hospital, in a tertiary care paediatric CF
unit. The inclusion criteria were children with cystic fibrosis,
diagnosed by at least two positive sweat chloride tests
(pilocarpine iontophoresis sweat test) and/or recognized CF
mutations, requiring IV antibiotics. None were equipped with a
functioning totally implantable device. Patients were consecu-
tively and prospectively recruited. The PICC procedure was
initiated in January 2004, and data for all patients who met the
inclusion criteria were collected until December 2007. The
catheters were always inserted by only 2 operators working as a
team (a paediatrician trained in PICC in neonates and other
central devices, assisted by a nurse), according to a protocol
which emphasized PICC insertion under strict sterile condi-
tions. This study was done in accordance with the recommen-
dations of the ethics committee of our institution. Parents were
informed of the benefits and risks of the procedure and assent
was granted by the child.
1.2. Insertion procedure
The catheter and needle systems used in this study included a
2F catheter with a 22-gauge needle and 3F catheter with a 19
gauge needle (First PICC, Becton Dickinson). The PICC
placement was performed either in the operating theatre or in
the ward, using a sterile technique. Topical anaesthetic was
applied to the chosen site (basilica or cephalic vein) before the
procedure. Veins were assessed either by direct observation or
by palpation. The catheter was flushed with saline solution and
trimmed to the correct length, with care being taken not to cut
the guide wire inside the catheter. The patient was placed in
supine position, with the arm abducted to a 90° angle. The site
was cleaned with an antiseptic solution and sterile draping put
around. The vein was cannulated with the peeled-away
introducer needle. Then the stylet was removed from the
introducer and the catheter was threaded through the peel-away
sheath and advanced centrally. The guide wire was then
removed. Fixation was done using the oval plastic extremity of
the catheter by sterile adhesive bands and an adhesive bandage.
The position of the catheter was confirmed by X-ray or by
radioscopy if available. The PICC tip's position was deemed tobe in a correct central position if it was situated in the superior
vena cava, at the height of the carina and above the right lateral
border of the cardiac silhouette.
Subjective scales were used, at the end of the insertion
procedure, to assess the operators' technical difficulties (1 (no
difficulty) to 10 (maximum difficulty)), and for their satisfaction
(1 (worse) to 10 (best)). The patients' satisfaction was evaluated
for the school age children (1 (worse) to 10 (best)), taking into
account the pain and the discomfort of the procedure. We also
evaluated the overall duration of the procedure and the number
of attempts per child.
After 3 days patients were discharged and treatment
completed at home by a certified nurse. Small disposable
infusion devices infusion devices such as the Infusor® LV 10
(Baxter Laboratories), or a poly-isoprene latex free device,
Easypump® LT 125 were used for continuous IV perfusion.
This is standard practice in our unit, irrespective of the IVaccess
inserted. The puncture site and the subcutaneous pathway of the
catheter were checked every day for inflammation or induration,
by the nurse. The sterile dressing of the puncture site was
renewed every 5 days, or if blood was visible beneath the
dressing. At the end of the antibiotic course, prior to the removal
of the PICC the patients underwent an ultrasound-Doppler scan
of ipsi-lateral and contro-lateral central veins, in order to check
for deep venous thrombosis and/or clots at the tip of the catheter.
The catheter was then removed at home by children's nurse.
1.3. Statistical analysis
Results are expressed as means±standard deviation or median
(range). Statistical analysis (ANOVA) was performed using the
software package, NCSS 6.0.21 (Kaysville, UT). A p value b0.05
was considered significant.
2. Results
2.1. Demographic data
We included 24 children aged 10.2 years (0.3–17.3) who
underwent 44 procedures during the study period, for a total of
588 catheter-days. The sex ratio was M:F=1:0.6. Demographic
data and pulmonary function test results are summarised
Table 1. Fifty percent (22/44) of children underwent the
procedure once, 25.0% (11/44) twice, 18.2% (8/44) 3 times and
6.8% (3/44) 4 times. P. aeruginosa was identified in 93.2% (41/
328 S. Bui et al. / Journal of Cystic Fibrosis 8 (2009) 326–33144) of cases. IV antibiotics were administered in 56.1% (23/41)
cases for a primary colonisation and in 43.9% (18/41) for
chronic infections. In the latter cases physicians did not insert a
totally implantable venous access device in 5 cases due to
patients' refusal and in 1 case due to a contraindication of such a
device. Three children, who were chronically infected by S.
aureus alone, with an altered clinical status also benefited from
the procedure.
2.2. Success rate
The catheter was successfully inserted in 93.2% (41/44) of
cases in 87.5% (21/24) children. In the three cases in which the
catheter could not be inserted, the children had had prior
attempts at PICC insertion and numerous venous punctures in
the past. Insertion was on the anterior aspect of the forearm in
36/41 (87.8%) of cases, on the right side in 34.2% (14/41) of
cases. The total duration of the procedure was 32.5 (10–105)
minutes, and in most cases the actual duration of catheter
insertion was generally less than 10 min. The operators
encountered few difficulties, median (range) 2 (1–10) and the
number of attempts was 1 (1–5) per child. After 10 years of age,
the procedure was successful in 100% of cases, and operators
encountered less difficulties. In the youngest age group, i.e. less
than 1 year, the success rate was 75% (3/4). There was a positive
linear correlation between the age of patients and the operators'
satisfaction scores (r=0.3, pb0.05).
Initially, all procedures were conducted in the operating
theatre in order to minimise the risk of infection. In the final
study year, most were conducted in children's ward rooms
(73,9% (17/23) of cases), immediately after the child's arrival
and after careful cleaning and disinfection of the room. Inhaled
analgesia associated with topical anaesthesia (EMLA patch)
was provided in 72.7% (32/44) of cases (MEOPA gas: mixture
of 50% Nitrous Oxide and 50% Oxygen). In the remaining
patients, catheter placement in the operating theatre under
general anaesthesia was maintained, due to the following
reasons: two toddlers who were very agitated due to previous
multiple venous punctures (no physical contention is applied in
our unit), one 14 year-old boy who had a psychiatric disability,
and one 15 year-old girl who developed scary hallucinations
with the analgesic gas.
The sterile procedure was identical irrespective of whether it
was done in the operating theatre or in the ward.
After PICC insertion, the children received two antibiotics
simultaneously (ceftazidime [19 children], piperacillin/clavula-
nic acid [5], piperacillin/tazobactam [11] or ciprofloxacin [2] in
association with amikacin [22] or tobramycin [18]. Continuous
ceftazidime was administered in 47.5% (19/40) of cases.
Fourteen children received teicoplanine for concomitant S.
aureus infection. Eighty 3% of cases received a continuous
perfusion to maintain catheter patency without heparinisation of
the catheter. Regarding intermittent administrations, we inserted
a positive pressure occluder within the IV circuit at the external
end of the PICC (BD Posiflow Ref 385301) (6/41 cases). The
occluder was flushed with normal saline solution without
heparin. Overall, the catheter remained patent during the entire14 days in 40/41 cases. However, in 12.2% (5/41) of cases, an
obstruction of the catheter was observed. Most cases were due
to premature clamping of the line. In 4 children instillation of
urokinase successfully repermeated the catheter and the IV
course could be maintained till the end. In one case the
obstruction occurred after 3 repeated insertions on the same
arm, and the course was interrupted on day 13. Noteworthy, no
cases of PICC occlusion were observed when a positive
pressure occluder was used.
In summary, the overall success rate was 90.9% (40/44) (3
non-insertions and 1 late occlusion of the PICC).
2.3. Tolerance
No major side effects were reported and no cases of infection
were observed.
An ultrasound-Doppler scan performed in 33 patients at the
end of the antibiotic course showed total permeability of the
central veins. One child presented with venous inflammation/
irritation each time the procedure was performed, therefore an
allergic reaction to polyurethane was suspected. One child
vomited during MEOPA gas administration.
2.4. Satisfaction
The mean scores regarding the satisfaction (SDS) of the
operators and the school age children were high, median (range)
9.5 (1–10) and 8.0 (6–10), respectively. There was no
difference in patient satisfaction scores between those who
received the PICC only once and those who underwent the
procedure more times (median score 8, 8, 8 and 7 in patients
who received PICC once, twice, three times and four times,
respectively).The procedure was easier to perform in elder
children, since fewer venous punctures are generally required
and the toddlers included had already undergone multiple
venous punctures in the past. Moreover, inhaled analgesia is not
always well accepted or tolerated in some patients. Although,
we did not specifically evaluate the impact of the continuous
perfusion on patient's quality of life at home, there were no
specific complaints regarding this issue.
3. Discussion
In this study we have shown that in toddlers (and older
children) with CF, central catheters introduced via peripheral
veins are simple to use and provide a high satisfaction rate for
patients, although the analogic scale used in the present study
has never been validated. The device can safely be used at home
for antibiotic treatments even in patients aged less than 1 year.
The strength of the present study lies in the inclusion of
consecutive patients in whom the same type of catheters were
inserted by the same experienced operators, using a homo-
geneous standardized protocol, in a group of patients with CF
with a wide age range. However, this was not a randomized
study, comparing the advantages and disadvantages of different
devices.
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However, the procedure requires optimisation in the younger
age groups. PICCs are more stable than short peripheral
cannulae, as the lifespan of the latter is usually 2 to 4 days
[11,13]. Some authors have described a lifespan of 8.3 days in
CF patients, but the results were better for catheters with a larger
gauge [10]. PICCs require less frequent replacement, increasing
children's well-being [7], in particular the very young patients
who may be more susceptible to painful procedures. Schwengel
et al. have noted great satisfaction of patients and parents
regarding PICC use, with fewer needle punctures compared
with short peripheral cannulae [9].
With respect to tolerance, totally implantable venous access
devices may cause significant morbidity due to sepsis,
thrombosis, cardiac tamponnade, pain at port site, retained
central line fragments, etc. [1,4,6]. Complications for totally
implantable venous access in CF has been reported to occur in
42 to 54% of cases, requiring device removal in 40% of cases
[1,4]. In contrast, studies concerning such PICC devices in
neonates and older children with CF or cancer, report as in the
present study, a low rate of complications and good tolerance of
such devices (Table 2) [1,3,4,7,9,12,16,20,21,23,24,26,27].
Data from the present study confirm what has been reported
in the literature.Table 2
Published studies regarding peripherally-inserted central venous catheters in childre
Author (ref) Year Patients Age
median,
years
Cath Type Disease/
treatments
n n
Bui
(present study)
2008 24 10,2
(0,3 to 17,2)
44 First-PICC
BD
CF/ATB
Beardsall (26) 2007 – – 46,000 71% Vygon Neonates/
nutrition
8% Solely
Meddex
Gamulka
(16)
2005 99 13,6
(3 to 18)
99 Bard Neonates/
nutrition
Cancers/
chemother
Ainsworth
(7)
2004 262 – 262 – Neonates/
nutrition
Schwengel (9) 2004 49 –
(0 to 14)
49 Cook Inc. Surgery/A
Bloomington
Chow (27) 2003 – – 1650 Cook Inc. ATB Canc
chemotherBloomington
Tolomeo
(24)
2003 32 – 61 CF/ATB
Aitken (3) 2000 65 25,0
(7 to 49)
87 Bard CF/ATB
Jones (23) 2000 54 (1,2 to
36,9)
192 – CF/ATB
Bunting
(21)
2000 110 124 – CF/ATB
Thiagarajan (20) 1997 390 5,4
(0 to 22)
441 PerQcath
LCath
Neonates/
ATB
Cath = catheters, Throm = thrombosis, SVC Sd = superior vena cava syndrome, PE
ATB = antibiotics, CF = cystic fibrosis, – = no data available.The most often described complications with PICC, are
mechanical problems [3,4,16,20,23,24,26,27]. In the present
study, obstruction of the device was the main complication,
mainly due to errors of manipulation. The rate of obstruction of
the PICCs was lower compared to other studies in CF patients
[3,16,20,23]. The obstruction rate increases with smaller lumen
sizes [20]. As shown previously [28], urokinase facilitated
repermeation of the catheters, thus allowing us to end the IV
antibiotic course in most cases. To prevent such occlusion, in
PICC protocols in older children, catheter maintenance often
includes a continuous infusion [17] or heparinisation with 150
units of heparin every 24 h if it is used intermittently [16,17].
Nevertheless, in neonates, a Cochrane review has shown no
benefit regarding the prophylactic use of heparin in PICC [19].
In our series, continuous ceftazidime provided continuous
infusion. But whenever the antibiotics were administrated
intermittently, we have obtained good results using a positive
pressure occluder without heparin. In addition, no cases of deep
venous thrombosis was observed as described previously
[3,16,18]. Of note, symptomatic deep venous thrombosis
occurs mostly in adults, when PICC have been used for
chemotherapy and/or other cancer treatments [29]. In children
the rate of deep venous thrombosis is 7-fold greater for
chemotherapy compared to other treatments [18]. Nevertheless,n.
Insertion
success
rate
Thrombosis SVC
Sd
PE Local
inflammation
Sepsis PTX Mech
n (%) n (%) n
(%)
n
(%)
n (%) n (%) n (%) n (%)
93,2 0 0 0 1 (2) 0 0 5
(11)
– – – – – – – 82
(0,2)
100 4 (4) 0 0 1 (1) – 0 7 (7)
apy
– – – – – – – –
TB 100 0 0 0 0 1 (4) 0 0
er/
apy
– – – – – – – 11
(0,7)
100 – – – – – – 18
(30)
100 14 (16) 2 (2) 1
(4)
9 (10) – 3 (3) 6 (7)
96,3 6 (3) 2 (1) – 2 (1) – – 2 (1)
100 1 (1) 0 0 – 0 0 –
98 32 (7) – 0 8 (2) 9 (2) 0 49
(11)
= pulmonary embolism, PTX = pneumothorax, Mech = mechanical problem,
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recurrent deep venous thrombosis with PICCs, due to activated
protein C-resistance [22], and we should take into consideration
that in cystic fibrosis, inflammation, diabetes and parenteral
nutrition may be thrombogenic-associated factors.
Jones et al. have reported retention of broken central venous
catheters, which were tethered to the site of insertion [6]. A few
cases of retention have been described with PICC in very low
birth weigh infants. In most cases there were associated factors
such as bacteraemia and a long duration of catheterization [30,31].
In CF patients difficulties regarding PICC removal have also been
described [32]. Continuous traction or moderately strong pulling
maneuvers were successful in dislodging the catheters in most of
cases in which they were performed [32,33]. In our series, the site
of insertion was carefully cleaned in order to remove coagulated
blood, and the short duration of 14 days was probably insufficient
for tethering.
Operators should also be aware of the fact that incorrect tip
position can give rise to rare but potentially serious complica-
tions such as pericardial effusion or cardiac tamponnade (1.8/
1000 lines). Beardsall et al. recommend that tips should not be
placed in the right atrium [26]. In addition, they suggest that
monitoring of the PICC tip position over time is necessary. In
the present study, monitoring over time was not performed.
However, on initial chest X-rays, we verified that the tip of
First-PICC catheter was placed high above the right atrium and
superior to the superior venous cava-pericardium junction, as
stated earlier. Noteworthy, First PICCs does not require
opacification, as recommended by some authors for other
catheters [34].
We did not observe misplacement, pneumothorax, arterial
puncture and haemorrhage, or coiled catheters [27,28] in our
series [35,36]. Such complications using other types of central
catheters are more prevalent with decreasing age and weight of
children, especially in children less than 1 year [35,36]. In our
hands, outcome with 22-gauge First PICCs in 4 infants aged
less than 1 year has been favorable.
The last serious complication with central devices is sepsis,
especially in CF patients infected by S. aureus and/or
P. aeruginosa. The reported infection rate with respect to
other central devices such as subclavian or internal jugular
catheters lies between 2.9 and 5.8% [37,38], and for TIVD, 10%
[1,3,4]. In our series, we observed only one case of local
inflammation and no cases of septicaemia; As it is shown in
Table 2, infection rates with PICC are very low in neonates
[7,20], in older children in surgical wards [9], and in older
patients with CF [3,21,23].
From the economic standpoint, at this point in time, the cost
may be a factor limiting the extended use of such devices. The
cost for the personnel should include approximately 40 min per
procedure for a medical doctor and a nurse. The First-PICC
device itself costs approximately 80 €. In the future, with more
widespread use, the device may become more accessible. In
adults, some authors have used ultrasound guidance to increase
the success rate of the procedure [39].
In conclusion, although the results presented are in essence
the personal audit of trained operators, PICC are simple to use,the procedure can be performed in the ward, under local
anaesthesia and sedation. It is safe even in young patients and it
increases patients' satisfaction and patients' quality of life, as
the antibiotic treatment can be also administered at home. It may
increase the well-being of children with CF and prove an
effective means by which to deliver IV therapy in this
population.
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